Design, Synthesis, and Biological Activity of Marinacarboline Analogues as STAT3 Pathway Inhibitors for Docetaxel-Resistant Triple-Negative Breast Cancer
作者:Woong Sub Byun、Hyewon Lim、Junhwa Hong、Eun Seo Bae、Seok Beom Lee、Younggwan Kim、Jeeyeon Lee、Sang Kook Lee、Suckchang Hong
DOI:10.1021/acs.jmedchem.2c01115
日期:2023.2.23
triple-negative breast cancer (mTNBC) is a fatal type of breast cancer (BC), and signal transducer and activator of transcription 3 (STAT3) has emerged as an effective target for mTNBC. In the present study, compound MC0704 was found to be a novel synthetic STAT3 pathway inhibitor, and its potential antitumor activity was demonstrated using in vitro and in vivo models in docetaxel-resistant TNBC cells. Based
转移性三阴性乳腺癌 (mTNBC) 是一种致命类型的乳腺癌 (BC),信号转导和转录激活因子 3 (STAT3) 已成为 mTNBC 的有效靶点。在本研究中,化合物MC0704被发现是一种新型合成 STAT3 通路抑制剂,其潜在的抗肿瘤活性在多西紫杉醇耐药的 TNBC 细胞中使用体外和体内模型得到证实。基于 marinacarboline (MC),合成了一系列 β-咔啉衍生物,并研究了它们对多西紫杉醇耐药 MDA-MB-231 (MDA-MB-231-DTR) 细胞的抗肿瘤活性。结合抗增殖和 STAT3 抑制活性,MC0704被选为最有前途的 β-咔啉化合物。MC0704在体外有效地阻止了 MDA-MB-231-DTR 细胞的转移潜能,并且MC0704和多西他赛的组合在异种移植小鼠模型中表现出有效的抗肿瘤活性。这些发现表明,MC0704可以作为具有多西紫杉醇耐药性的 TNBC 患者的靶向治疗药物的主要候选药物。